达格列净联合二甲双胍治疗2型糖尿病的疗效及对糖脂代谢的影响

目的:探讨达格列净联合二甲双胍治疗2型糖尿病的疗效及对糖脂代谢的影响。方法:选择2018年1月-2020年1月在我院接受治疗的120例2型糖尿病患者,采用抽签法分为观察组(n=61)和对照组(n=59)。对照组给予二甲双胍治疗,观察组在对照组的基础上给予达格列净治疗。比较两组患者的临床疗效、治疗前后血清空腹血糖(FBG)、空腹胰岛素(FINS)、糖化血红蛋白(Hb Alc)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平、胰岛素β细胞功能指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR)的变化情况及不良反应的发生情况。结果:治疗后,观察组和对照组总有效率分别为93.62%,74.47%,观察组显著高于对照组(P0.05);两组FBG、FINS、HbAlc、TC、TG、LDL-C水平及HOMA-IR均较治疗前显著降低,且观察组上述指标均明显低于对照组(P0.05),两组HDL-C水平和HOMA-β均较治疗前显著升高,且观察组显著高于对照组(P0.05);两组不良反应总发生率为6.56%、8.47%,组间比较差异无统计学意义(P0.05)。结论:达格列净联合二甲双胍治疗2型糖尿病的效果显著优于单用二甲双胍治疗,其可有效改善患者糖脂代谢水平,且不会增加不良反应。

Efficacy of Dagulijing Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus and Its Effect on the Glucose and Lipid Metabolism

ABSTRACT Objective: To study the efficacy of dagulijing combined with metformin in the treatment of type 2 diabetes mellitus and its effect on glucose and lipid metabolism. Methods: 120 patients with type 2 diabetes who were treated in our hospital from January 2018 to January 2020 were selected and divided into the observation group (n=61) and the control group (n=59) by drawing lots. The control group was treated with metformin, and the observation group was treated with daguernet on the basis of control group. The clinical efficacy, changes of serum fasting blood glucose (FBG), fasting insulin (FINS), glycosylated hemoglobin (HbAlc), total cholesterol (TC), three acyl glycerin (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) levels and insulin beta cell function index (HOMA-beta), insulin resistance index (HOMA IR) before and after treatment and the occurrence of adverse reactions were compared between two groups. Results: After treatment, the total effective rate was 93.62% in the observation group and 74.47% in the control group, which was significantly higher in the observation group than that in the control group (P<0.05). The levels of FBG, FINS, HbAlc, TC, TG, ldl-c and HOMA-IR in the two groups were significantly lower than those in the control group before treatment, and the above indexes in the observation group were significantly lower than those in the control group (P<0.05). The total incidence of adverse reactions between the two groups was 6.56% and 8.47%, no significant difference was found between the two groups (P>0.05). Conclusion: The effect of dagulijing combined with metformin in the treatment of type 2 diabetes was significantly better than that of metformin alone, which could effectively improve the glucose and lipid metabolism of patients without increasing adverse reactions.